Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220014/S008

CraniSeal Dural Sealant

Pramand, LLC · Decision date Aug 25, 2025

FDA DECISIONP220014/S008

What did the FDA approve?

FDA records P220014/S008 as a supplement to PMA P220014, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 25, 2025.

FDA approval order statement

Approval for a change to the Indications for Use to include patients greater than or equal to 13 years of age.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Aug 25, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P220014/S008
Regulatory pathway
PMA supplement
Applicant
Pramand, LLC
Product code
NQR
Decision code
APPR
Decision date
Aug 25, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Applicant
Pramand, LLC
Product code
NQR
FDA device class
3

For the original device and its historical approval scope, see PMA P220014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220014 · Original PMA

    CraniSeal Dural Sealant

  2. P220014/S008 received

    Application receipt date recorded by FDA.

  3. P220014/S008 · FDA decision

    Normal 180 Day Track

  4. P220014/S009 · Related supplement

    CraniSeal Dural Sealant

  5. P220014/S010 · Related supplement

    CraniSeal Dural Sealant

  6. P220014/S011 · Related supplement

    CraniSeal Dural Sealant

  7. P220014/S012 · Related supplement

    CraniSeal Dural Sealant

  8. P220014/S013 · Related supplement

    CraniSeal Dural Sealant

Timeline entries are records held by MedtechLedger for P220014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220014

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA approvalJul 6, 2023FDA
Pramand, LLCPMA supplementOct 10, 2025FDA
Pramand, LLCPMA supplementJan 16, 2026FDA
Pramand, LLCPMA supplementApr 1, 2026FDA
Pramand, LLCPMA supplementAug 5, 2026FDA
Pramand, LLCPMA supplementOct 1, 2026FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA supplementAug 31, 2026FDA
Stryker Leibinger GmbH & Co. KGPMA supplementJul 15, 2026FDA
Pramand, LLCPMA supplementApr 1, 2026FDA
Integra LifeSciences CorporationPMA supplementFeb 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pramand, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., Suite 210, Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records